Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rhinoconjunctivitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44353   clinical trials with a EudraCT protocol, of which   7380   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    244 result(s) found for: Rhinoconjunctivitis. Displaying page 6 of 13.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2013-000617-20 Sponsor Protocol Number: SMART_2 Start Date*: 2013-08-23
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Dose Finding Study of the Efficacy of LAIS® Mites Sublingual tablets in patients suffering from house dust mite-induced allergic rhinoconjunctivitis A prospective, double-blind, placebo-controlle...
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004126-32 Sponsor Protocol Number: T502-SIT-041 Start Date*: 2020-12-18
    Sponsor Name:Inmunotek S.L.
    Full Title: A prospective open follow-up study with 10 000 mTU/mL mannan-conjugated birch pollen allergoids administered subcutaneously to participants of the T502-SIT-020 trial
    Medical condition: Treatment of birch pollen-induced allergic rhinitis or rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000414-11 Sponsor Protocol Number: 603-PG-PSC-191 Start Date*: 2012-08-31
    Sponsor Name:LETI Pharma GmbH
    Full Title: Multicenter, placebo-controlled, long-term study of Depigoid Birch 5000 in adults and adolescents with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma
    Medical condition: Seasonal allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma due to birch pollen allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) CZ (Completed) FI (Completed) PL (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2007-003345-33 Sponsor Protocol Number: GPE03 Start Date*: 2007-11-01
    Sponsor Name:Curalogic A/S
    Full Title: A randomized, double-blind, parallel group, placebo-controlled study to assess the efficacy and safety of two doses of oral microencapsulated grass pollen extract administered prior to and during t...
    Medical condition: Seasonal rhino-conjunctivitis due to grass pollen allergy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) LV (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000971-97 Sponsor Protocol Number: AL-X-01 Start Date*: 2017-08-23
    Sponsor Name:ALK Abelló A/S
    Full Title: Safety and tolerability of shortened up-dosing with Alutard SQ
    Medical condition: Allergic rhinoconjunctivitis induced by grass pollen, birch pollen and house dust mites
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014962 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-000446-34 Sponsor Protocol Number: MT-18 Start Date*: 2020-07-14
    Sponsor Name:ALK-Abelló A/S
    Full Title: A 28-day, single-armed, open-label trial to evaluate safety of the house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet in adolescent subjects (12-17 years of age) with HDM allergic...
    Medical condition: Allergic rhinitis/rhinoconjunctivitis induced by house dust mite
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-008448-26 Sponsor Protocol Number: 603-PG-PSC-173 Start Date*: 2009-10-20
    Sponsor Name:LETI Pharma GmbH
    Full Title: Randomized, double-blind, parallel group, multicenter study to evaluate the efficacy and safety of four doses of depigmented glutaraldehyde polymerized birch pollen allergenic extract (Depigoid® Bi...
    Medical condition: Allergic rhinitis and/or rhinoconjunctivitis, with or without intermittent asthma, caused by birch pollen.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001723 Allergic rhinitis LLT
    9.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000984-15 Sponsor Protocol Number: PQBirch204 Start Date*: 2015-07-13
    Sponsor Name:Allergy Therapeutics (UK) Ltd
    Full Title: A multi-centre, double-blind, placebo-controlled study to explore the safety and efficacy of Birch Modified Allergen Tyrosine adsorbed + MPL (POLLINEX® Quattro Plus 1.0 mL Birch [PQ Birch]) in subj...
    Medical condition: Seasonal allergic rhinoconjunctivitis due to birch pollen
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002317-34 Sponsor Protocol Number: AL2101av Start Date*: 2021-12-20
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicenter, randomized, open label clinical trial for safety evaluation of an allergen immunotherapy with an accelerated dose escalation schedule using one strength of an aluminium hydroxide ads...
    Medical condition: moderate to severe seasonal allergic rhinitis or rhinoconjunctivitis with or w/o asthma caused by birch pollen allergens
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000333-31 Sponsor Protocol Number: PQGrass205 Start Date*: 2017-09-13
    Sponsor Name:Allergy Therapeutics (UK) Ltd.
    Full Title: A multi-centre, randomised, double blind, placebo controlled study to determine the optimal effective and safe dose of Pollinex Quattro Grass 1.0 mL (Allergy Therapeutics, (UK) Ltd.) for the treatm...
    Medical condition: Grass pollen-induced seasonal allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000051-27 Sponsor Protocol Number: PM/0041 Start Date*: 2016-09-22
    Sponsor Name:HAL Allergy B.V.
    Full Title: A randomized, double-blind, placebo-controlled (DBPC) parallel-group multi-centre study to assess the efficacy and safety of PURETHAL Mites subcutaneous immunotherapy (SCIT) in patients with allerg...
    Medical condition: Allergic rhinitis/rhinoconjunctivitis (ARC) caused by house dust mite (HDM) allergy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004855 10001724 Allergic rhinitis (excl hay fever) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) HU (Completed) ES (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000416-28 Sponsor Protocol Number: 6043-PG-PSC-192 Start Date*: 2012-08-22
    Sponsor Name:LETI Pharma GmbH
    Full Title: A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients with Allergic Rhinitis and/or Rhinoconjunctivi...
    Medical condition: Allergic Rhinitis and/or Rhinoconjunctivitis with or without Intermittent Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    14.1 100000004855 10001705 Allergic asthma LLT
    14.1 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004185-14 Sponsor Protocol Number: CDPG103ADE01 Start Date*: 2012-02-29
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of intraseasonal specific short-term immunotherapy with depigmented glutaraldeh...
    Medical condition: Allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039776 Seasonal allergic rhinitis LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001855-38 Sponsor Protocol Number: 8237-003 Start Date*: 2012-09-03
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase IIb, Randomized, Placebo-Controlled, Dose-Finding Clinical Trial to Study the Safety and Efficacy of MK-8237 using an Environmental Exposure Chamber in Subjects with House Dust induced Alle...
    Medical condition: House Dust Induced Rhinitis/Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001723 Allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005678-76 Sponsor Protocol Number: AIFANumberFARM94793N Start Date*: 2013-08-30
    Sponsor Name:ALLEGRIA onlus
    Full Title: Twenty-four month, multicenter, prospective, randomized, double-blind, placebo controlled, parallel-group study to evaluate the efficacy, safety, tolerability, and cost-effectiveness of allergen sp...
    Medical condition: Allergic asthma to house dust mites
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10003558 Asthma extrinsic LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000615-31 Sponsor Protocol Number: DIA-EC-Cupa1-01-22 Start Date*: 2022-05-26
    Sponsor Name:Diater Laboratorio de Diagnósticos y Aplicaciones Terapéuticas
    Full Title: Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial in parallel groups which evaluates the clinical efficacy and safety of immunotherapy with the purified major aller...
    Medical condition: Allergic patients to the Cupressaceae pollen with moderate/severe allergic rhino conjunctivitis with or without controlled asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000548-25 Sponsor Protocol Number: AL1605av Start Date*: 2018-06-18
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicentre, randomized, open label clinical trial for safety evaluation of an accelerated high dose escalation schedule with one strength for an allergen immunotherapy with an aluminium hydroxid...
    Medical condition: Patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without asthma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10039776 Seasonal allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    21.1 100000004855 10001705 Allergic asthma LLT
    21.1 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-005550-30 Sponsor Protocol Number: SB/0042 Start Date*: 2014-06-10
    Sponsor Name:HAL Allergy B.V.
    Full Title: A randomized, double-blind, placebo-controlled (DBPC), parallel group study to assess the clinical efficacy and safety of SUBLIVAC FIX Birch immunotherapy in patients suffering from allergic rhinit...
    Medical condition: Moderate to severe birch pollen induced allergic rhinitis/rhinoconjunctivitis with or without mild to moderate persistent asthma.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) SK (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000057-23 Sponsor Protocol Number: AV-G-01 Start Date*: 2011-05-26
    Sponsor Name:ALK-Abello S.A.
    Full Title: Estudio abierto para valorar la tolerabilidad de la inmunoterapia con AVANZ Phleum pratense
    Medical condition: Rinoconjuntivitis alérgica con o sin asma debido a la sensibilidad al polen de gramineas.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-021775-80 Sponsor Protocol Number: ProGIT Start Date*: 2010-12-06
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Explorative Untersuchung zum Einfluss der Vitamin D-vermitteltenr Modulation der initialen subkutanen Gräserpollen-spezifischen Immuntherapie bei Allergikern mit Gräserpollen-induzierter Rhinokonju...
    Medical condition: Allergische Rhinokonjunktivitis mit oder ohne allergischem Asthma verursacht durch Gräserpollen
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 09 08:37:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA